報價延遲最少15分鐘:2026/03/10 00:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.58 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-40.46/6.53
|
|
企業價值
61.45M
|
| 資產負債 |
|
每股賬面淨值
-25.16
|
| 現金流量 |
|
現金流量率
0.33
|
| 損益表 |
|
收益
56.59M
|
|
每股收益
6.61
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule. |
